- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma ; volume:9 ; number:6 ; year:2020 ; pages:629-639
Liver cancer ; 9, Heft 6 (2020), 629-639
- Urheber
-
Kudo, Masatoshi
- DOI
-
10.1159/000512170
- URN
-
urn:nbn:de:101:1-2020120923295190299397
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kudo, Masatoshi
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy